TapewireFind a company

person · Reporting owner

Oren Ilan

Disclosed activity across 2 companies

Tapewire entity
29297
SEC CIK
0001643073

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Roivant Sciences Ltd.ROIV · Entity 3185DirectorSeptember 16, 2026September 18, 2026
Sio Gene Therapies Inc.AXON · Entity 130622DirectorJune 06, 2018June 14, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Roivant Sciences Ltd.

Report date September 16, 2026 · Filed September 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect123,680 Reported balance After 2026-09-16 transaction · row 1
1 source row

Row 1 · 2026-09-16 · Grant · Acquired 5,054 · Balance 123,680

F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.57 · Expires 2036-09-15Direct10,531 Reported balance After 2026-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-16 · Grant · Acquired 10,531 · Balance 10,531

F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Sio Gene Therapies Inc.

Report date June 06, 2018 · Filed June 14, 2018

This filing explicitly reported no securities owned.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 16, 2026 Filed Sep 18, 2026 23:06 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 10,531 $0.00 Strike: $39.57 $0.00
Disclosure

SEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · derivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,531

Underlying: Common Shares · 10,531 shares

Expires 2036-09-15

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 23:06 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 5,054 $0.00 $0.00
Disclosure

SEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,680

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 22:42 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 2,378 $40.94 $97,355.32
Disclosure

SEC source: 0001635088-26-000092 · wk-form4_1789425749.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,626

F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
July 17, 2026 Filed Jul 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 775 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-029191 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,004

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
April 17, 2026 Filed Apr 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 95 $29.83 $2,833.85
Disclosure

SEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,229

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
April 17, 2026 Filed Apr 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 896 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,324

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
January 20, 2026 Filed Jan 23, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 124 $22.98 $2,849.52
Disclosure

SEC source: 0001140361-26-002086 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,428

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
January 20, 2026 Filed Jan 23, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 1,164 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-002086 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,552

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
October 20, 2025 Filed Oct 23, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 281 $17.74 $4,984.94
Disclosure

SEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,388

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
October 20, 2025 Filed Oct 23, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 1,507 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,669

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 33,726 $0.00 Strike: $13.77 $0.00
Disclosure

SEC source: 0001140361-25-034931 · form4.xml · derivative · entry 3

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 2,043 $13.77 $28,132.11
Disclosure

SEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,162

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
September 10, 2025 Filed Sep 13, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 14,524 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,205

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

Read SEC document
April 17, 2025 Filed Apr 22, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 64 $10.15 $649.60
Disclosure

SEC source: 0001140361-25-014800 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,500

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
April 17, 2025 Filed Apr 22, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,635 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-014800 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,564

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
April 17, 2025 Filed Jul 22, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 115 $11.65 $1,339.75
Disclosure

SEC source: 0001140361-25-026649 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,681

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
April 17, 2025 Filed Jul 22, 2025 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,296 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-026649 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,796

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
January 23, 2025 Filed Jan 28, 2025 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 313 $11.21 $3,508.73
Disclosure

SEC source: 0001140361-25-002100 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,929

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
January 23, 2025 Filed Jan 28, 2025 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,386 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-002100 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,242

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
October 21, 2024 Filed Oct 24, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,303 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-044059 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,856

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
September 12, 2024 Filed Sep 17, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 3,487 $12.12 $42,262.44
Disclosure

SEC source: 0001140361-24-041234 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,553

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
September 10, 2024 Filed Sep 13, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 27,894 $0.00 Strike: $12.19 $0.00
Disclosure

SEC source: 0001140361-24-040985 · form4.xml · derivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,894

Underlying: Common Shares · 27,894 shares

Expires 2034-09-09

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.

Read SEC document
September 10, 2024 Filed Sep 13, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 16,406 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-040985 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,040

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.

Read SEC document
July 23, 2024 Filed Jul 26, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 215 $11.01 $2,367.15
Disclosure

SEC source: 0001140361-24-034281 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,634

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
July 23, 2024 Filed Jul 26, 2024 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,440 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-034281 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,849

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
April 24, 2024 Filed Apr 27, 2024 01:01 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 54 $10.90 $588.60
Disclosure

SEC source: 0001140361-24-022620 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,409

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Read SEC document
April 24, 2024 Filed Apr 27, 2024 01:01 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,121 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-022620 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,463

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
January 19, 2024 Filed Jan 24, 2024 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 3,366 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-003551 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,342

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
October 16, 2023 Filed Oct 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,269 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-048776 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,976

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
September 18, 2023 Filed Sep 21, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 8,703 $11.17 $97,212.51
Disclosure

SEC source: 0001140361-23-044652 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,707

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4

Read SEC document
September 12, 2023 Filed Sep 15, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 26,595 $0.00 Strike: $11.22 $0.00
Disclosure

SEC source: 0001140361-23-044042 · form4.xml · derivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,595

Underlying: Common Shares · 26,595 shares

Expires 2033-09-11

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date.

Read SEC document
September 12, 2023 Filed Sep 15, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 17,825 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-044042 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,410

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date.

Read SEC document
July 03, 2023 Filed Jul 7, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 1,472 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-033545 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,585

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
April 03, 2023 Filed Apr 6, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 1,942 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-016867 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,113

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,010 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-000729 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,171

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
October 31, 2022 Filed Nov 2, 2022 21:58 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 2,796 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-039661 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,161

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document
September 15, 2022 Filed Sep 20, 2022 01:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 71,850 $0.00 Strike: $3.50 $0.00
Disclosure

SEC source: 0001140361-22-033877 · form4.xml · derivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,850

Underlying: Common Shares · 71,850 shares

Expires 2032-09-14

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date.

Read SEC document
September 15, 2022 Filed Sep 20, 2022 01:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 52,142 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-033877 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,365

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date.

Read SEC document
July 20, 2022 Filed Jul 25, 2022 10:05 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 3,223 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-026614 · doc4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,223

F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.